ConductScience.org, home

Trial · NCT01940887

Adverse events202

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
seriousIntraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept03220
seriousIntraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept13201
seriousInvasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousInvasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept13201
seriousLentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousLentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept03200
seriousLung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousLung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept13201
seriousMetastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousMetastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept03200
seriousProstate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept33223
seriousProstate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept03200
seriousProstate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousProstate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept03200
seriousRenal cell carcinoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept03220
seriousRenal cell carcinoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept13201
seriousUterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)E10030 + Bevacizumab or Aflibercept13221
seriousUterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)Sham + Bevacizumab or Aflibercept03200
seriousCerebral haematomaNervous system disordersE10030 + Bevacizumab or Aflibercept13221
seriousCerebral haematomaNervous system disordersSham + Bevacizumab or Aflibercept03200

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01940887/events?page=8